Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
ASCO 2022 Head and Neck Cancer
In this video series Dr. Kathryn Gold, Medical Oncologist specializing in lung, head, and neck cancers, Professor, Department of Medicine, UC San Diego, and Dr. Siddharth Sheth, Medical oncologist, Assistant Professor of Medicine, Division of Medical Oncology, UNC Chapel Hill, discuss the newest updates in head and neck cancer, presented at ASCO 2022.
Please feel free to offer comments and raise questions in our
discussion forums.
Dr. Singhi's reprise about appropriate treatment, "Right patient, right time, right team".
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.